Robert W. Baird Trims Curis (NASDAQ:CRIS) Target Price to $6.00

Curis (NASDAQ:CRIS) had its target price cut by Robert W. Baird to $6.00 in a research note published on Monday, May 7th. They currently have an outperform rating on the biotechnology company’s stock.

CRIS has been the topic of several other reports. Zacks Investment Research downgraded shares of Curis from a hold rating to a sell rating in a report on Tuesday, January 9th. ValuEngine upgraded shares of Curis from a strong sell rating to a sell rating in a research report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $4.50.

NASDAQ CRIS opened at $0.60 on Monday. The company has a debt-to-equity ratio of 2.24, a current ratio of 3.60 and a quick ratio of 3.60. Curis has a 52 week low of $0.52 and a 52 week high of $0.59. The company has a market cap of $86.69 million, a P/E ratio of -1.67 and a beta of 1.29.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.02. The business had revenue of $2.47 million for the quarter, compared to analyst estimates of $2.30 million. Curis had a negative net margin of 472.13% and a negative return on equity of 247.46%. research analysts forecast that Curis will post -0.37 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Arnhold LLC purchased a new position in Curis during the first quarter worth about $1,907,000. GSA Capital Partners LLP boosted its stake in Curis by 104.2% during the first quarter. GSA Capital Partners LLP now owns 1,913,208 shares of the biotechnology company’s stock worth $1,250,000 after buying an additional 976,151 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in Curis during the first quarter worth about $523,000. Millennium Management LLC boosted its stake in Curis by 1,341.7% during the fourth quarter. Millennium Management LLC now owns 3,149,154 shares of the biotechnology company’s stock worth $2,204,000 after buying an additional 2,930,725 shares during the period. Finally, Two Sigma Investments LP boosted its stake in Curis by 1,816.6% during the fourth quarter. Two Sigma Investments LP now owns 854,944 shares of the biotechnology company’s stock worth $598,000 after buying an additional 810,336 shares during the period. Hedge funds and other institutional investors own 45.83% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply